24.4 C
New York
Sunday, July 3, 2022

Why Was MEI Pharma (MEIP) Stock Declined In Extended Trades Thursday?

MEI Pharma Inc. (MEIP) has plunged -45.86% at $0.98 in after-hours trading hours on the last check Thursday. The stock of MEI Pharma (MEIP) gained 0.56% to complete the last trading session at $1.81. The price range of the company’s shares was between $1.795 and $1.835. It traded 2.18 million shares, which was above its daily average of 1.44 million shares over 100 days.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


MEI Pharma (MEIP) shares have dropped by -4.23% in the last five days, while they have subtracted -7.65% in the last month. MEIP stock began falling after the US Food and Drug Administration (FDA) asked the company that one of its candidates be studied further.

MEIP needs to pursue which study?

MEI Pharma (MEIP) is a late-stage drug organization zeroed in on creating likely new treatments for disease. MEIP’s arrangement of medication up-and-comers contains different clinical-stage resources, including zandelisib, at present in continuous clinical preliminaries which might uphold advertising endorsements with the FDA and other administrative specialists around the world. Every one of MEIP pipeline applicants uses an alternate instrument of activity with the target of creating separated remedial to address neglected clinical requirements and convey further developed advantage to patients either as independent medicines or in the mix with other helpful choices.

MEI Pharma (MEIP) yesterday gave an update after a new gathering with the FDA to examine the quest for a promoting approval for zandelisib.

  • Zandelisib is a phosphatidylinositol-3-kinase (“PI3K”) inhibitor drug up-and-comer and MEIP has been looking for the sped-up endorsement pathway under 21 CFR Part 314.500, for that competitor in view of information created by the single-arm Phase 2 TIDAL review.
  • In the gathering, the FDA educated MEIP regarding its place that a randomized preliminary is presently expected to enough survey drug viability and wellbeing of PI3K inhibitor drug up-and-comers, including zandelisib.
  • In light of this view, the organization deterred a recording in view of Phase 2 TIDAL review information and underlined that the organizations proceeded with endeavors with the continuous, randomized Phase 3 COASTAL review according to plan.

How MEIP will continue further?

In like manner, in accordance with the FDA’s proposal, MEI Pharma (MEIP) doesn’t plan to present an FDA-promoting application in light of the single-arm Phase 2 TIDAL review. What’s more, while the FDA expressed that wellbeing on the 60 mg discontinuous timetable seems sensible, it prescribed proceeded with portion investigation to additional help the current portion and routine. In view of current projections, MEIP has adequate money for tasks to finish the COASTAL review enlistment in 2024.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles